SUPN News and Press, Supernus Pharmaceuticals Inc. From 05/09/23

2023-05-09 21:43:08 ET Supernus Pharmaceuticals, Inc. (SUPN) Q1 2023 Results Conference Call May 09, 2023 04:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Call Participants Andrew Tsai - Jeff...

2023-05-09 16:20:35 ET Supernus Pharmaceuticals press release ( NASDAQ: SUPN ): Q1 GAAP EPS of $0.29 beats by $0.55 . Revenue of $153.8M (+0.8% Y/Y) beats by $14.78M . FY23 Total revenues to be $580M - $620M, vs. $599.79M consensus. For further details se...

First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 Qelbree ® net product sales of $25.8 million, compared to $8.3 million in first quarter 2022 GOCOVRI ® net product sales of $26.0 million, compared to $22...

ROCKVILLE, Md., May 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supern...

ROCKVILLE, Md., April 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial...

2023-04-04 03:44:22 ET Biopharmaceutical company, Supernus Pharmaceuticals ( NASDAQ: SUPN ) has paid out the total principal amount due of $402.5M under its 0.625% convertible senior notes due 2023. This is in addition to payment of the remaining outstanding interest due o...

ROCKVILLE, Md., April 03, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that it has paid the total principal amount ...

ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the Supernus Pharmaceuticals management...

ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supe...

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2022 Earnings Conference Call February 28, 2023, 04:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Call Participants David Amsellem - Piper Sandler Andre...